PTGX · Healthcare
Protagonist Therapeutics Inc
22/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
30
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$9.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About PROTAGONIST THERAPEUTICS INC
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of…
Who's behind the signal
Every informed buyer we can see on PTGX, across all three feeds.
Hedge funds · 5
Bridgewater Associates (Dalio)
New position
Citadel Advisors
Increased +38%
AQR Capital Management
Increased +71%
Duquesne Family Office (Druckenmiller)
Unchanged
Gotham Asset Mgmt (Greenblatt)
Decreased −2%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
PROTAGONIST THERAPEUTICS INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
1
New positions
2
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
0.0%
Position change
NEW
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+38%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+71%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.6×
% of portfolio
0.6%
Position change
—
0.6% of Duquesne Family Office's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−2%
0.0% of Gotham Asset Mgmt's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to PROTAGONIST THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell PROTAGONIST THERAPEUTICS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime